NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks.
In the past week, the Nordic biotech and healthcare stocks rose 7%. 2cureX rose 90% without any news and is now up more than 500% in the past month. Several companies released their Q1 earnings, with Genmab reporting impressive growth and Gubra with a solid guidance. Furthermore, Zealand Pharma got new price targets at more than twice their current stock price.
Latest news for the Danish biotech companies
Acarix AB has developed a technology to identify heart diseases. Moving forward, product sales are the main driver for the stock.
No news in the past week
Ascendis Pharma develops so-called prodrugs, which are medications that start in an inactive form and become active once inside the body. The main stock price driver going forward is the development and commercialization of its TransCon technology.
Ascendis is sharing its latest endocrinology rare disease data at the ESPE & ESE 2025 these days
Biosergen is developing BSG005 to treat serious and life-threatening fungal infections safely and with limited side effects, contrary to current drugs. The main price triggers are centered around product development and the ongoing clinical trials
Biosergen announced the proposal of Marco Taglietti as a new board member
Cessatech develops pain treatments for children. The company is finalizing its phase 3 study for its lead candidate, and the main price driver will be the commercialization for this product.
No news in the past week
Curasight is focused on diagnosing (uTRACE) and treating cancer (uTREAT) through targeted radionuclide therapy. The benefit is treating cancer at the cellular level without harming healthy cells. The main driver of the stock moving forward is the financing of the portfolio as well as pipeline and partnership development. You can read our full investment case here (in Danish).
The subscription period of Curasight’s rights issue of MDKK 100 is ongoing. The subscription price is DKK 1.98. The stock trades at 2.20, and the theoretical stock price is DKK 3.72. Read more here.
Curasight also announced Premier Research as the CRO for their phase 1 trial investigating uTREAT for the treatment of brain cancer patients.
DanCann Pharma focuses on discovering, developing, and producing medical cannabis for pain and neurological conditions. The stock price drivers are regulatory progress and sales development.
No news in the past week
Evaxion Biotech develops personalized immunotherapies and vaccines, with recent advancements in their cancer vaccine candidate EVX-01. Clinical trial outcomes and technological innovations currently drive the stock price.
No news in the past week
ExpreS2ion provides protein production technologies for vaccine development and has its own pipeline. Key stock drivers include pipeline progression and licensing agreements.
No news in the past week
Fluoguide develops tumor-targeted products that make cancer visible on imaging solutions to improve cancer surgery outcomes, especially within brain and head & neck cancer surgery. The main stock driver is the clinical validation of their imaging technology and additional partnerships.
No news in the past week
Genmab focuses on creating differentiated antibody therapeutics for the treatment of lymphatic leukemia and solid tumors. Genmab has developed Darzalex, with sales of nearly USD 12 billion in 2024. The stock performance is primarily driven by product sales and pipeline developments.
Genmab released its first quarter results with sales of MUSD 715, and guidance of USD 3.3-3.7 billion for 2025. Darzalex grew sales of almost 30%.
Genmab also got several new price targets. Carnegie increased their price target from DKK 2,263 to DKK 2,288, Handelsbanken increased their price target from DKK 1,350 to DKK 2,000, Cowen lowered it from DKK 1,431 DKK to DKK 1,360, UBS from DKK 2,700 to DKK 2,600, and Nykredit from DKK 2,000 to DKK 1,750.
Gubra offers preclinical contract research services and develops treatments for metabolic diseases. Key stock drivers are partnerships and progress in their internal drug pipeline.
Gubra announced its first quarter results with revenue shrinking 11.5% to MDKK 57.5. The company keeps its guidance of organic revenue growth of 10-20% and an adjusted EBIT of 25-31% for the CRO business.
Gubra also got a new chairman, and the co-founder also stepped onto the board.
Initiator Pharma develops treatments for erectile dysfunction and neuropathic pain. The main stock catalyst is the outcome of clinical trials.
Initiator Pharma released its first quarter results for 2025 without any news.
IO Biotech is developing immune-modulating therapies for cancer, with a focus on conditions like melanoma. Stock performance is driven by clinical trial advancements.
No news in the past week
Pila Pharma is working on TRPV1 antagonists aimed at treating type 2 diabetes. Early clinical data and funding developments are key stock drivers.
No news in the past week
Saniona focuses on ion channel-targeted therapies, including rare eating disorders. The main stock driver is the progression of their clinical pipeline and the approval of the weight loss drug Tesofensine in Mexico.
No news in the past week
Scandion Oncology is developing treatments to overcome chemotherapy resistance in cancer patients. The company has recently faced significant financial challenges, thus, financial stability is the main driver for the stock price.
No news in the past week
SynAct Pharma develops drugs targeting inflammatory diseases through melanocortin pathways. Clinical milestones significantly influence stock performance
SynAct Pharma will host its Capital Markets Day on June 4
ViroGates provides prognostic products for acute care settings to improve patient triage. Stock drivers include hospital adoption rates and revenue growth.
No news in the past week
Y-mAbs Therapeutics develops antibody-based therapies for pediatric cancers. Stock performance is driven by regulatory approvals and commercialization efforts.
Y-mAbs Therapeutics announced their DANYELZA is now recommended by the NCCN as a category 2A treatment option for high-risk neuroblastoma.
Zealand Pharma specializes in peptide-based treatments for metabolic and gastrointestinal diseases. The stock has seen increased awareness following the obesity hype, and advancements in their late-stage pipeline and partnerships are key stock price influencers.
Zealand Pharma announced its first quarter results with revenues of MDKK 8.1 and 2025 guidance for net operating expenses of BDKK 2,0-2,5. The company’s CEO said, “Zealand Pharma has never been in a stronger position than we are today – financially, organizationally and in terms of our clinical development pipeline.”
Following the Q1 earnings, DNB lowered their price targets from DKK 1,000 to 950, SEB to DKK 780 from DKK 950, and Goldman Sachs to DKK 806 from DKK 873.
2cureX offers the IndiTreat platform for individualized cancer treatment testing. The main stock driver is the adoption of their technology by hospitals and subsequent sales growth.
No news in the past week
The latest share price developments for the Danish biotech stocks
On average, the Danish biotech and healthcare stocks rose 7%. 2cureX delivered another crazy week with a return of 90% following a 59% return in the week prior to last week. The stock is up 521% in the past month without any news. Scandion Oncology also rose 47% without any news. Most eye-catching were Genmab‘s revenue growth in Q1 to MUSD 715, Zealand Pharma with new price targets at more than twice the current stock price, and Curasight chose its CRO for their phase 1 study with uTREAT in brain cancer. Curasight is currently raising MDKK 100 of capital. You can read more below.
Overview of share price development in the past week, year-to-date, and the last twelve months
DanCann Pharma does not appear on the list due to data issues.
Curasight is raising capital; you can participate!
Curasight A/S is a Danish biotech company listed on the Swedish stock exchange. Curasight focuses on diagnosing (uTRACE) and treating (uTREAT) cancer in a more gentle and effective way than conventional methods. Both products are injected into the bloodstream, where they bind to uPAR receptors found only in cancer cells. uTRACE is used to identify cancer cells via a PET scanner, while uTREAT emits radiation that kills cancer cells with a limited and thus gentle irradiation. Curasight will raise MDKK 100 for significant clinical studies, of which 47% is secured, and the subscription period runs until May 16.
AcouSort finished their rights issue last week, raising MSEK 24.9 before issuing costs. The rights issue was subscribed to a total of 73%.
